Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EmbectaEMBC -2.86%51 3-Year EPS without NRI Growth Rate is -14.90% as of Jun. 2026. GuruFocus rates EMBC with a GF Score™ of 51/100 and a GF Value™ of $12.13 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 662 Medical Devices & Instruments companies, Embecta ranks worse than 77.49% on this metric.
During the past 12 months, Embecta's average EPS without NRI Growth Rate was -30.10% per year.
During the past 3 years, the average EPS without NRI Growth Rate was -14.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -21.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of Embecta was -14.20% per year. The lowest was -30.40% per year. And the median was -20.65% per year.
Embecta (NAS:EMBC) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Embecta 3-Year EPS without NRI Growth Rate Related Terms
EMBC vs SMTI, OSUR, NNNN: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Embecta's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embecta 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embecta's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Embecta's 3-Year EPS without NRI Growth Rate falls into.
Embecta 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -14.90% mean?
Embecta (EMBC) has a 3-Year EPS without NRI Growth Rate of -14.90% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Embecta and its competitors. According to the industry distribution chart, Embecta ranks #513 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 77.5%.
Is Embecta's 3-Year EPS without NRI Growth Rate too high?
Embecta's current 3-Year EPS without NRI Growth Rate is -14.90%. Based on the distribution chart, Embecta ranks #513 out of 662 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Embecta has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Embecta's 3-Year EPS without NRI Growth Rate compare to SMTI and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Embecta ranks #513 out of 662 companies for 3-Year EPS without NRI Growth Rate. This places Embecta in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Embecta and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embecta's current 3-Year EPS without NRI Growth Rate is -14.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embecta stock overvalued right now?
Based on GuruFocus' analysis, Embecta (EMBC) is currently considered Possible Value Trap. The stock's GF Value™ is $12.13, compared to a current price of $5.08 — trading 58.1% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -14.90%. Embecta's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Embecta (EMBC), the current 3-Year EPS without NRI Growth Rate is -14.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embecta (EMBC) Overvalued in 2026?
Based on GuruFocus' analysis, Embecta stock appears to be undervalued.
The current stock price of $5.08 is trading 58.1% below its estimated GF Value™ of $12.13.
GuruFocus considers Embecta to be Possible Value Trap.
Key valuation signals for EMBC:
3-Year EPS without NRI Growth Rate: -14.90%
GF Value™: $12.13 vs. price of $5.08 (58.1% below fair value)
No single metric tells the full story. See the EMBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
51GF Score
Get the complete analysis for EMBC
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMBC has been successfully added to your 
